# PRODUCT QUALITY MICROBIOLOGY FILING CHECKLIST

**NDA Number:** 203985  
**Applicant:** Novartis Pharmaceuticals Corp.  
**Letter Date:** 2/29/2012  
**Drug Name:** Afinitor zDISPERZ  
**NDA Type:** 505(b)(1)  
**Stamp Date:** 2/29/2012

The following are necessary to initiate a review of the NDA application:

<table>
<thead>
<tr>
<th>Content Parameter</th>
<th>Yes</th>
<th>No</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Is the product quality microbiology information described in the NDA and organized in a manner to allow substantive review to begin? Is it legible, indexed, and/or paginated adequately?</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Has the applicant submitted an overall description of the manufacturing processes and microbiological controls used in the manufacture of the drug product?</td>
<td>X</td>
<td></td>
<td>3.2.P.3.3</td>
</tr>
<tr>
<td>3. Has the applicant submitted protocols and results of validation studies concerning microbiological control processes used in the manufacture of the drug product?</td>
<td>X</td>
<td></td>
<td>(b) (4)</td>
</tr>
<tr>
<td>4. Are any study reports or published articles in a foreign language? If yes, has the translated version been included in the submission for review?</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. Has the applicant submitted preservative effectiveness studies (if applicable) and container-closure integrity studies?</td>
<td></td>
<td></td>
<td>N/A</td>
</tr>
<tr>
<td>6. Has the applicant submitted microbiological specifications for the drug product and a description of the test methods?</td>
<td>X</td>
<td></td>
<td>3.2.P.3.4: control-critical-steps.pdf</td>
</tr>
<tr>
<td>7. Has the applicant submitted the results of analytical method verification studies?</td>
<td>X</td>
<td></td>
<td>(b) (4)</td>
</tr>
<tr>
<td>8. Has the applicant submitted all special/critical studies/data requested during pre-submission meetings and/or discussions?</td>
<td></td>
<td></td>
<td>N/A</td>
</tr>
<tr>
<td>9. Is this NDA fileable? If not, then describe why.</td>
<td>X</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Additional Comments: None

Steven P. Donald, M.S.  
Reviewing Microbiologist  
3/22/2012

Stephen E. Langille, Ph.D.  
Microbiology Secondary Reviewer/Team Leader  
3/22/2012
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

----------------------------------------------------
STEVEN P DONALD
03/23/2012

STEPHEN E LANGILLE
03/23/2012
Product Quality Microbiology Review

3/20/2012

NDA: 203985

Drug Product Name
   Proprietary: Afinitor zDISPERZ
   Non-proprietary: everolimus

Review Number: 1

Dates of Submission(s) Covered by this Review

<table>
<thead>
<tr>
<th>Submit</th>
<th>Received</th>
<th>Review Request</th>
<th>Assigned to Reviewer</th>
</tr>
</thead>
</table>

Submission History (for amendments only): N/A

Applicant/Sponsor
   Name: Novartis Pharmaceuticals Corporation
   Address: One Health Plaza, East Hanover, New Jersey 07936-1080
   Representative: Yanina Gutman, Drug Regulatory Affairs
   Telephone: 862 778 1767

Name of Reviewer: Steven P. Donald, M.S.

Conclusion: Recommended for approval
Product Quality Microbiology Data Sheet

A. 1. TYPE OF SUBMISSION: Original NDA

2. SUBMISSION PROVIDES FOR: The manufacture of an oral drug product

3. MANUFACTURING SITE:
Novartis Pharma AG, Lichtstrasse 35, CH-4056 Basel, Switzerland, and
Novartis Pharma Stein AG, Schaffhauserstrasse, CH-4332 Stein, Switzerland

4. DOSAGE FORM, ROUTE OF ADMINISTRATION AND STRENGTH/POTENCY: Tablet, oral, 2 mg, 3 mg and 5 mg dispersible tablets in blister packs.

5. METHOD(S) OF STERILIZATION: Non sterile product

6. PHARMACOLOGICAL CATEGORY: Antineoplastic

B. SUPPORTING/RELATED DOCUMENTS: None

C. REMARKS: eCTD format; new age appropriate formulation for pediatric patients; pediatric exclusivity determination request.

filename: [redacted]
Executive Summary

I. Recommendations

A. **Recommendation on Approvability** -
   NDA 203985 is recommended for approval from the standpoint of product quality microbiology.

B. **Recommendations on Phase 4 Commitments and/or Agreements, if Approvable** – N/A

II. Summary of Microbiology Assessments

A. **Brief Description of the Manufacturing Processes that relate to Product Quality Microbiology** -
   The drug substance will be [reddacted]

B. **Brief Description of Microbiology Deficiencies** – No product quality microbiology deficiencies were identified based upon the information provided.

C. **Assessment of Risk Due to Microbiology Deficiencies** – N/A

III. Administrative

A. **Reviewer's Signature** ____________________________
   Steven P. Donald, M.S.

B. **Endorsement Block** ____________________________
   Stephen E. Langille, Ph.D.
   Senior Microbiology Reviewer

C. **CC Block**
   N/A

3 Page(s) has been Withheld in Full as b4 (CCI/TS) immediately following this page
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

STEVEN P DONALD
03/21/2012

STEPHEN E LANGILLE
03/22/2012